Mivebresib + Navitoclax + Ruxolitinib
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelofibrosis (MF)
Conditions
Myelofibrosis (MF)
Trial Timeline
Mar 17, 2021 → Jul 28, 2023
NCT ID
NCT04480086About Mivebresib + Navitoclax + Ruxolitinib
Mivebresib + Navitoclax + Ruxolitinib is a phase 1 stage product being developed by AbbVie for Myelofibrosis (MF). The current trial status is terminated. This product is registered under clinical trial identifier NCT04480086. Target conditions include Myelofibrosis (MF).
What happened to similar drugs?
2 of 19 similar drugs in Myelofibrosis (MF) were approved
Approved (2) Terminated (3) Active (14)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04480086 | Phase 1 | Terminated |
Competing Products
20 competing products in Myelofibrosis (MF)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 36 |
| Nusivertib + Ruxolitinib + Momelotinib | Sumitomo Pharma | Phase 1/2 | 39 |
| Ruxolitinib + Navitoclax | AbbVie | Phase 2 | 35 |
| ABBV-744 + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Placebo for Navitoclax + Ruxolitinib + Navitoclax | AbbVie | Phase 3 | 40 |
| Navitoclax + Venetoclax | AbbVie | Pre-clinical | 26 |
| Navitoclax + Ruxolitinib + Best Available Therapy (BAT) | AbbVie | Phase 3 | 44 |
| NS-018 + Best Available Therapy | Nippon Shinyaku | Phase 2 | 27 |
| AZD1480 | AstraZeneca | Phase 1 | 29 |
| Bomedemstat | Merck | Phase 2 | 31 |
| Peginterferon alfa-2a | Merck | Phase 2 | 27 |
| Bomedemstat | Merck | Phase 1/2 | 32 |
| MBG453 + NIS793 + Spartalizumab + Decitabine | Novartis | Phase 1 | 21 |
| PIM447 + Ruxolitinib + LEE011 | Novartis | Phase 1 | 29 |
| LDE225 + INC424 | Novartis | Phase 1/2 | 32 |
| Imatinib mesylate | Novartis | Phase 2 | 35 |
| Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793 | Novartis | Phase 1/2 | 24 |
| Ruxolitinib + Ruxolitinib Placebo | Novartis | Phase 3 | 32 |
| Ruxolitinib | Novartis | Pre-clinical | 30 |
| ruxolitinib | Novartis | Phase 2 | 35 |